Company Transition and Focus - Whitehawk Therapeutics relaunched in March 2025, marking a transition into an ADC-focused company[6] - The company's strategy involves advancing a portfolio of ADC assets rapidly towards clinical trials[7, 9] - Whitehawk anticipates filing INDs for all three assets by mid-2026[9] ADC Technology Platform - Whitehawk utilizes an advanced ADC technology platform engineered for minimal off-target toxicity, greater stability, and a higher therapeutic index[9, 12] - The platform incorporates a proprietary TOPO1 inhibitor payload and a highly stable, cleavable linker[13] - The goal is to improve the therapeutic index compared to first-generation ADCs[14, 15] ADC Programs and Targets - HWK-007 targets PTK7, an oncofetal pseudokinase overexpressed in various tumors, including NSCLC (~63K US metastatic cases annually) and ovarian cancer (~4K)[11, 18] - HWK-016 targets MUC16, a glycoprotein overexpressed in cancers affecting women, such as ovarian (~4K), endometrial, and cervical cancers[11, 18] - HWK-206 targets SEZ6, a CNS protein upregulated in tumors of neuroendocrine origin, including SCLC (~18K) and neuroendocrine tumors (~5K)[11, 18] Financial and Strategic Positioning - Whitehawk's cash runway is expected to fund operations into 2028, including anticipated key clinical data[20]

Company Strategy & Portfolio - Whitehawk Therapeutics is transitioning into an ADC-focused company, leveraging advanced ADC technology and targeting significant patient populations[6, 7] - The company's portfolio includes three assets (HWK-007, HWK-016, and HWK-206) rapidly progressing to clinical trials, with all three INDs anticipated in the next 15 months[7, 9] - Whitehawk's ADC platform is engineered for minimal off-target toxicity, greater stability, and a higher therapeutic index[9, 12] ADC Technology & Efficacy - Whitehawk utilizes a proprietary TOPO1 inhibitor payload and a highly stable, cleavable linker to improve the therapeutic index of its ADCs[13] - Switching to an advanced ADC platform technology delivers efficacy gains compared to 1st generation ADCs, as demonstrated by increased Overall Response Rates (ORR) in various cancer indications[17] - For example, in SEZ6 targeting for Small Cell Lung Cancer (SCLC), next-wave ADCs like ABBV-706 achieved a 61% ORR, compared to 19% with 1st generation ADCs[17] Target & Clinical Development - HWK-007 targets PTK7, which is overexpressed in a broad spectrum of cancers, including Non-Small Cell Lung Cancer (NSCLC) and Ovarian cancer, with potential to outperform current ADC benchmarks[20, 29, 31] - HWK-016 targets MUC16, a glycoprotein overexpressed in cancers affecting women, with a Phase 1 trial planned in ovarian cancer[40, 50] - HWK-206 targets SEZ6, a CNS protein upregulated in tumors of neuroendocrine origin, with a Phase 1 trial planned in SCLC and Neuroendocrine Neoplasms (NENs)[55, 65] Financial Outlook - The company's cash runway is expected to fund operations into 2028, including anticipated key clinical data[3, 67]